6-((1,3-dioxoisoindolin-2-yl)oxy)hexanoic acid | 1101114-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 6-((1,3-dioxoisoindolin-2-yl)oxy)hexanoic acid
• 英文别名: 6-[(1,3-Dihydro-1,3-dioxo-2h-isoindol-2-yl)oxy]hexanoic acid；6-(1,3-dioxoisoindol-2-yl)oxyhexanoic acid
• CAS: 1101114-27-5
• 化学式: C₁₄H₁₅NO₅
• 分子量: 277.277
• InChiKey: ULYFTEZZAQMGPR-UHFFFAOYSA-N

物化性质

• 沸点：
  475.4±47.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  83.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-((1,3-dioxoisoindolin-2-yl)oxy)hexanoic acid 在 吡啶 、 4-二甲氨基吡啶 、 氯化亚砜 、 1,2-二氯乙烷 、 甲基肼 作用下， 以 二氯甲烷 为溶剂， 反应 46.0h， 生成 N-((6-((benzyloxy)amino)-6-oxohexyl)oxy)-3-methylbenzamide
  参考文献：
  名称：

  Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells

  摘要：

  The synthesis and biological evaluation of new potent hydroxamate-based HDAC inhibitors with a novel alkoxyamide connecting unit linker region are described. Biological evaluation includes MTT and cellular HDAC assays on sensitive and chemoresistant cancer cell lines as well as HDAC profiling of selected compounds. Compound 191 (LMK235) (N-((6-(hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide) showed similar effects compared to vorinostat on inhibition of cellular HDACs in a pan-HDAC assay but enhanced cytotoxic effects against the human cancer cell lines A2780, Cal27, Kyse510, and MDA-MB231. Subsequent HDAC profiling yielded a novel HDAC isoform selectivity profile of 19i in comparison to vorinostat or trichostatin A (TSA). 19i shows nanomolar inhibition of HDAC4 and HDAC5, whereas vorinostat and TSA inhibit HDAC4 and HDAC5 in the higher micromolar range.

  DOI：

  10.1021/jm301254q
• 作为产物：
  描述：

  6-羟基己酸叔丁酯 在 盐酸 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 12.0h， 生成 6-((1,3-dioxoisoindolin-2-yl)oxy)hexanoic acid
  参考文献：
  名称：

  [EN] ANTI-CD70 ANTIBODY DRUG CONJUGATES
  [FR] CONJUGUÉS DE MÉDICAMENT ANTICORPS ANTI-CD70

  摘要：

  本发明涉及抗CD70抗体以及包含至少一个非天然编码氨基酸的抗体药物偶联物。在此公开了具有一个或多个非天然编码氨基酸的αCD70抗体，并且进一步公开了抗体药物偶联物，其中本发明的αCD70抗体与一个或多个毒素偶联。进一步还公开了使用此类非天然氨基酸抗体药物偶联物的方法，包括治疗、诊断和其他生物技术应用。

  公开号：

  WO2013192360A1

文献信息

• A Chemoselective and Modular Post‐Synthetic Multi‐Functionalization of NHC–Platinum Complexes
  作者：Georges Dahm、Etienne Borré、Gilles Guichard、Stéphane Bellemin‐Laponnaz

  DOI：10.1002/ejic.201500116

  日期：2015.4

  We report oxime ligation in combination with metal ligand exchange as a novel orthogonal and practical approach to the multifunctionalization of NHC–platinum complexes. This strategy, which enables strong diversity enhancement of metallodrug candidates, could also be applied to selective bioconjugation.

  我们报告了肟连接与金属配体交换相结合，作为一种新颖的正交和实用的 NHC-铂配合物多功能化方法。这种策略可以增强候选金属药物的多样性，也可以应用于选择性生物偶联。
• [EN] PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT D'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE À LA PROSTATE
  申请人：AMBRX INC

  公开号：WO2013185117A1

  公开（公告）日：2013-12-12

  This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

  本发明涉及前列腺特异性膜抗原（PSMA）抗体及包含至少一个非天然编码氨基酸的抗体药物偶联物。公开了具有一个或多个非天然编码氨基酸的αPSMA抗体，以及进一步公开了抗体药物偶联物，其中本发明的αPSMA抗体与一个或多个毒素偶联。还公开了非天然氨基酸多拉司汀类似物，这些类似物在翻译后进一步修饰，以及实现这些修饰的方法和纯化这些多拉司汀类似物的方法。通常，修饰的多拉司汀类似物包括至少一个肟、羰基、二羰基和/或羟基胺基团。进一步公开了使用此类非天然氨基酸抗体药物偶联物、多拉司汀类似物和修饰的非天然氨基酸多拉司汀类似物的方法，包括治疗、诊断和其他生物技术用途。
• [EN] COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES<br/>[FR] COMPOSITIONS CONTENANT DES DÉRIVÉS DE DOLASTATINE LIÉS À DES ACIDES AMINÉS NON NATUREL
  申请人：AMBRX INC

  公开号：WO2012166560A1

  公开（公告）日：2012-12-06

  Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

  披露的是非天然氨基酸和杜洛司他汀类似物，其中包括至少一种非天然氨基酸，以及制造这种非天然氨基酸和多肽的方法。杜洛司他汀类似物可以包括广泛的可能性功能，但通常至少具有一个肟、羰基、二羰基和/或羟基胺基团。还披露了在翻译后进一步修改的非天然氨基酸杜洛司他汀类似物，实施这种修改的方法，以及纯化这种杜洛司他汀类似物的方法。通常，修改后的杜洛司他汀类似物至少包括一个肟、羰基、二羰基和/或羟基胺基团。进一步披露了使用这样的非天然氨基酸杜洛司他汀类似物和修改后的非天然氨基酸杜洛司他汀类似物的方法，包括治疗、诊断和其他生物技术应用。
• Ligand‐Enabled β‐Methylene C(sp ³ )−H Arylation of Masked Aliphatic Alcohols
  作者：Guoqin Xia、Zhe Zhuang、Luo‐Yan Liu、Stuart L. Schreiber、Bruno Melillo、Jin‐Quan Yu

  DOI：10.1002/anie.202000632

  日期：2020.5.11

  salicylic-aldehyde-derived L,X-type directing group with an electron-deficient 2-pyridone ligand to enable the β-methylene C(sp3 )-H arylation of aliphatic alcohols, which has not been possible previously. Notably, this protocol is compatible with heterocycles embedded in both alcohol substrates and aryl coupling partners. A site- and stereo-specific annulation of dihydrocholesterol and the synthesis of a key

  尽管有最新进展，但是反应性和位点选择性仍然是C（sp3）-H键官能化方法实际应用的重大障碍。在这里，我们描述了一个系统，该系统将水杨醛衍生的L，X型导向基团与缺电子的2-吡啶酮配体结合在一起，以使脂肪族醇的β-亚甲基C（sp3）-H芳基化以前有可能。值得注意的是，该方案与嵌入在醇底物和芳基偶联伙伴中的杂环兼容。二氢胆固醇的位点和立体特异性环合以及恩格列酮的关键中间体的合成说明了该方法的实用性。
• “Singapore Green”: A New Fluorescent Dye for Microarray and Bioimaging Applications
  作者：Junqi Li、Shao Q. Yao

  DOI：10.1021/ol802700w

  日期：2009.1.15

  We have synthesized Singapore Green (SG), a structural hybrid of Tokyo Green and Rhodamine 110. This new dye is a green light-emitting substitute for 7-aminocoumarin, a blue fluorescent dye widely used in enzymatic assays. SG-conjugated peptide substrates were successfully synthesized and used in microarray-based protease substrate profiling and live-cell imaging experiments.

  我们已经合成了新加坡绿色（SG），它是东京绿色和若丹明110的结构混合物。这种新染料是7-氨基香豆素的绿色发光替代物，7-氨基香豆素是一种广泛用于酶促测定的蓝色荧光染料。SG结合的肽底物已成功合成，并用于基于微阵列的蛋白酶底物谱分析和活细胞成像实验中。